Availability and affordability of anticancer medicines is a matter of great concern especially for low and middle income countries e.g., Pakistan. Prime focus of this study was to evaluate the availability of anticancer medicines in public and private sectors, and their affordability among patients with different income levels.
A descriptive, cross-sectional survey was conducted in 22 cancer care hospitals (18 public hospitals and 04 private hospitals) and 44 private pharmacies in Punjab, Pakistan. All (n = 4400) participants were ≥18 years of age. Data were collected at different intervals and analyzed by using Statistical Packages for Social Sciences (IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp.)
A total of 4913 patients were approached, and 4400 responded to the survey (response rate = 89.6%). Non-hodgkin lymphoma (12.3%), breast cancer (8.6%), and leukemia (7.6%) were the most prevailing cancers. Conventional medicines like cisplatin, cyclophosphamide, and etoposide were the most prescribed medicines. Oncologists were reluctant to prescribe newer anticancer medicines due to high prices. Originator brands (OBs) were more readily available (52.5%) but less affordable (53.4%); whereas, lowest price generics (LPGs) were less available (28.1%) but more affordable (67.9%). Anticancer medicines were more affordable by the high income class patients than the low income class patients.
The availability of both OBs and LPGs was greater at private hospitals and pharmacies as compared to public hospitals. The high income class had more affordability of both OBs and LPGs; however, LPGs were more affordable for all income classes.
Shahid Mahmood, et al., Annual cancer registry report-2016, of the Shaukat Khanum Memorial Cancer Hospital & Research Center, PAKISTAN. 2016: Pakistan.
Kantarjian HM, et al. Cancer drugs in the United States: Justum Pretium—the just price. J Clin Onco. 2013;31(28):3600–4. CrossRef
Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. Proc Am Soc Clin Oncol. 2009;
Bhurgri Y, et al. Pakistan-country profile of cancer and cancer control 1995-2004. J Pak Med Assoc. 2006;56(3):124. PubMed
Nishtar DS. National Action Plan for prevention and control of non-communicable diseases and. Health Promotion. 2004:162.
Azhar Qureshi, Burhan Ahmed Khan, and Qasim Mahmood, Overview : National Cancer Control Plan (Pakistan). 2006.
Vogler S, Zimmermann N, Habl C. Understanding the components of pharmaceutical expenditure-overview of pharmaceutical policies influencing expenditure across European countries. GaBi J. 2013;2(3):178–87. CrossRef
Atif, M., et al., Pharmaceutical Policy in Pakistan, in Pharmaceutical Policy in Countries with Developing Healthcare Systems. 2017, Springer. p. 25–44.
Haider, M., Half of Pakistan population lives in poverty: UN report . The news, 2014.
Jamshed, S.Q., et al., The pharmaceutical industry, intellectual property rights and access to medicines in Pakistan, in The New Political Economy of Pharmaceuticals. 2013, Springer. p. 167–184.
World Health Organization, Price, availability and affordability: an international comparison of chronic disease medicines. 2006.
Government of the Punjab. Bureau of Statistics Punjab 2015.
Raosoft. Sample size calculator. 2015 [cited 2016 December 2015]; Available from: http://www.raosoft.com/samplesize.html.
Fedral Board of Revenue. Tax Payer Online Verification. Available from: https://e.fbr.gov.pk/registration/onlinesearchtaxpayer.aspx.
Neeshat, M., PharmaGuide, ed. M.Q. Neeshat. 2016, Karachi, Pakistan.
Irfan SM, Ijaz A, Shahbaz S. An assessment of service quality of private hospitals in Pakistan: a patient perspective. Indian Journal of Commerce and Management Studies. 2011;2(2):20–32.
Yohana E, Kamuhabwa A, Mujinja P. Availability and affordability of anticancer medicines at the ocean road cancer Institute in Dar es salaam. Tanzania East Afr J Public Health. 2011;8(1):52–7. PubMed
Irfan SM, Ijaz A, Shahbaz S. An assessment of service quality of private hospitals in Pakistan: a patient perspective. Ind J Commerce & Management Studies. 2011;2(2):20–32.
Milani, B., W. Scholten, and W.H. Organization, The world medicines situation 2011 : Access to controlled medicines 2011.
Ministry of Health Government of Pakistan and World Health Organization, Pharmaceutical Country Profile for Pakistan. 2010.
- Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan
Muhammad Rehan Sarwar
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II